RESUMO
OBJECTIVES: Determine the incremental diagnostic yield of prenatal exome sequencing (pES) over chromosome microarray (CMA) or G-banding karyotype in fetuses with central nervous system (CNS) abnormalities. METHODS: Data were collected via electronic searches from January 2010 to April 2022 in MEDLINE, Cochrane, Web of Science and EMBASE. The NHS England prenatal exome cohort was also included. Incremental yield was calculated as a pooled value using a random-effects model. RESULTS: Thirty studies were included (n = 1583 cases). The incremental yield with pES for any CNS anomaly was 32% [95%CI 27%-36%; I2 = 72%]. Subgroup analysis revealed apparent incremental yields in; (a) isolated CNS anomalies; 27% [95%CI 19%-34%; I2 = 74%]; (b) single CNS anomaly; 16% [95% CI 10%-23%; I2 = 41%]; (c) more than one CNS anomaly; 31% [95% Cl 21%-40%; I2 = 56%]; and (d) the anatomical subtype with the most optimal yield was Type 1 malformation of cortical development, related to abnormal cell proliferation or apoptosis, incorporating microcephalies, megalencephalies and dysplasia; 40% (22%-57%; I2 = 68%). The commonest syndromes in isolated cases were Lissencephaly 3 and X-linked hydrocephalus. CONCLUSIONS: Prenatal exome sequencing provides a high incremental diagnostic yield in fetuses with CNS abnormalities with optimal yields in cases with multiple CNS anomalies, particularly those affecting the midline, posterior fossa and cortex.
Assuntos
Hidrocefalia , Malformações do Sistema Nervoso , Gravidez , Feminino , Humanos , Estudos Prospectivos , Malformações do Sistema Nervoso/diagnóstico , Malformações do Sistema Nervoso/genética , Cariotipagem , Cariótipo , Feto/anormalidades , Diagnóstico Pré-Natal , Ultrassonografia Pré-NatalRESUMO
DExD/H-box RNA helicases (DDX/DHX) are encoded by a large paralogous gene family; in a subset of these human helicase genes, pathogenic variation causes neurodevelopmental disorder (NDD) traits and cancer. DHX9 encodes a BRCA1-interacting nuclear helicase regulating transcription, R-loops, and homologous recombination and exhibits the highest mutational constraint of all DDX/DHX paralogs but remains unassociated with disease traits in OMIM. Using exome sequencing and family-based rare-variant analyses, we identified 20 individuals with de novo, ultra-rare, heterozygous missense or loss-of-function (LoF) DHX9 variant alleles. Phenotypes ranged from NDDs to the distal symmetric polyneuropathy axonal Charcot-Marie-Tooth disease (CMT2). Quantitative Human Phenotype Ontology (HPO) analysis demonstrated genotype-phenotype correlations with LoF variants causing mild NDD phenotypes and nuclear localization signal (NLS) missense variants causing severe NDD. We investigated DHX9 variant-associated cellular phenotypes in human cell lines. Whereas wild-type DHX9 was restricted to the nucleus, NLS missense variants abnormally accumulated in the cytoplasm. Fibroblasts from an individual with an NLS variant also showed abnormal cytoplasmic DHX9 accumulation. CMT2-associated missense variants caused aberrant nucleolar DHX9 accumulation, a phenomenon previously associated with cellular stress. Two NDD-associated variants, p.Gly411Glu and p.Arg761Gln, altered DHX9 ATPase activity. The severe NDD-associated variant p.Arg141Gln did not affect DHX9 localization but instead increased R-loop levels and double-stranded DNA breaks. Dhx9-/- mice exhibited hypoactivity in novel environments, tremor, and sensorineural hearing loss. All together, these results establish DHX9 as a critical regulator of mammalian neurodevelopment and neuronal homeostasis.
Assuntos
Doença de Charcot-Marie-Tooth , Transtornos do Neurodesenvolvimento , Animais , Humanos , Camundongos , Linhagem Celular , Doença de Charcot-Marie-Tooth/genética , RNA Helicases DEAD-box/genética , Diclorodifenil Dicloroetileno , DNA Helicases , Mamíferos , Proteínas de Neoplasias/genéticaRESUMO
FETAL PHENOTYPE: A couple of Ashkenazi Jewish descent was referred for an early anatomy scan at 14 + 2 weeks of gestation following a previous pregnancy termination due to posterior encephalocele and enlarged kidneys. The index pregnancy was also positive for several fetal abnormalities, including enlarged kidneys with cystic dysplasia and abnormal cerebellar morphology highly suggestive of Joubert syndrome. GENETIC DIAGNOSTIC TEST PERFORMED, RESULT, AND INTERPRETATION: Trio exome sequencing revealed compound heterozygosity for variants in the TMEM67 gene: a known pathogenic maternally inherited variant found in trans with a paternal intronic variant of unknown significance. RNA analysis revealed that the intronic variant creates a cryptic acceptor splice site in intron 12, leading to the insertion of 22 bp and causing a frameshift with a premature stop codon. This analysis enabled the reclassification of the intronic variant to likely pathogenic. IMPLICATIONS AND NOVELTY: This information empowered the couple to make informed reproductive choices and opt for preimplantation genetic testing (PGT) for future pregnancies.
Assuntos
Disseminação de Informação , Sítios de Splice de RNA , Éxons , Mutação , ÍntronsRESUMO
Hamartomatous polyposis syndromes (HPS) are rare cancer-predisposing disorders including Juvenile polyposis (JPS), Peutz-Jeghers (PJS) and PTEN hamartomatous syndromes (PHS). Penetrant mutations in corresponding genes (SMAD4, BMPR1A, STK11, PTEN and AKT1), are usually diagnosed via a next-generation-sequencing gene panel (NGS-GP) for tailored surveillance and preimplantation testing for monogenic disorders (PGT-M). Five probands with HPS phenotype, with no genetic diagnosis per genetic workup, underwent whole-genome sequencing (WGS) that identified structural genetic alterations: two novel inversions in BMPRA1 and STK11, two BMPR1A-deletions, known as founders among Bukharan Jews, and BMPR1A microdeletion. BMPR1A inversion was validated by "junction fragment" amplification and direct testing. PGT-M was performed via multiplex-PCR and enabled successful birth of a non-carrier baby. WGS may be considered for HPS patients with no NGS-GP findings to exclude structural alterations.
Assuntos
Polipose Adenomatosa do Colo , Síndrome do Hamartoma Múltiplo , Polipose Intestinal , Síndromes Neoplásicas Hereditárias , Polipose Adenomatosa do Colo/genética , Síndrome do Hamartoma Múltiplo/genética , Humanos , Polipose Intestinal/epidemiologia , Polipose Intestinal/genética , Síndromes Neoplásicas Hereditárias/genética , Sequenciamento Completo do GenomaRESUMO
BACKGROUND: HNF1B deletion/intragenic mutations are the most commonly identified genetic cause of congenital anomalies of the kidney and urinary tract (CAKUT) suggested by fetal ultrasound findings such as: parenchymal hyperechogenicity, overt cystic changes or gross morphological urinary system (UT) abnormalities. The postnatal evolution of these 17q12 deletions encompassing the HNF1B gene-associated findings has not been assessed in depth. METHODS: In this observational study, we present postnatal follow-up findings in 5 of 6 cases (one pregnancy was terminated on parental request) of fetal-onset cystic/hyperechogenic kidneys eventually diagnosed with 17q12 microdeletion encompassing the HNF1B gene between 2009 and 2017. RESULTS: Complete normalization of kidney parenchymal abnormalities and of depressed neonatal renal function was observed in 4/5 and 5/5 patients within 2-4.9 years and 1.5-8 months, respectively. All 5 patients had preserved normal renal function at 3-11 years of follow-up. The evolving later-onset renal features included: hypomagnesemia, hyperuricemia, urinary tract infection (UTI), and bilateral grade 3-4 vesicoureteral reflux and bladder diverticula in 3, 3, 2, and 1 patient, respectively. HNF1B gene deletion-associated extra-renal manifestations with delayed presentation were global developmental delay/autistic spectrum disorder (ASD), rolandic-type seizures, overweight, and borderline fasting hyperglycemia observed in 1-2 patients each. Family history was positive for small-size or asymptomatic cystic kidneys with normal function, diabetes mellitus, seizures, and mental/psychiatric problems in 3/6 cases. CONCLUSIONS: Fetal-onset HNF1B deletion-associated kidneys' parenchymal abnormalities confirmed postnatally with initially depressed renal function might undergo complete resolution within several years and few months, respectively. However, later-onset urinary tract, metabolic, and neurodevelopmental features of this mutation might appear over years. Therefore, genetic molecular evaluation/diagnosis and continuous follow-up for evolving features are mandatory in affected children.
RESUMO
PURPOSE: This research sought to understand IVF-physicians' knowledge of, experience with, and attitudes toward fertility preservation for cancer patients. METHODS: A 35-question, self-report survey request was emailed to IVF providers who were registered on the IVF-Worldwide.com network (3826 clinics). Physicians submitted responses on the IVF-Worldwide.com website. Survey results were reported as a proportion of the responding clinics. RESULTS: Survey responses were completed by 321 (8.4%) globally distributed IVF clinics, representing 299,800 IVF cycles. Of these clinics, 86.6% (278) performed fertility preservation, treating approximately 6300 patients annually. However, 18.4% of the centers reported that patients sought advice independently, without an oncologist's referral. Ovarian tissue cryopreservation was performed by 37.7% of the clinics, yet 52.6% considered the procedure experimental. IVM was performed by 16.5% of responding clinics. A majority (63.6%) of the clinics selected treatment protocols based on each patient's malignancy. Most respondents (76.3%) disagreed that fertility preservation was not yet successful enough to make it an available option. However, 44.2% believed that pregnancy rates following oocyte cryopreservation could not be determined because not enough oocyte cryopreservation patients had completed embryo transfer. CONCLUSIONS: Most clinics performed fertility preservation, tailoring protocols to each patient's disease and condition. Almost 20% of patients sought advice independently, indicating that more effort is needed to encourage oncologists to refer patients. Most survey respondents believed that data was not yet available on either live birth outcomes or the best protocol for each disease. Therefore, long-term study must continue, with the establishment of interim milestones and an outcome-tracking registry.
Assuntos
Atitude do Pessoal de Saúde , Preservação da Fertilidade/psicologia , Fertilização in vitro/métodos , Infertilidade Feminina/terapia , Neoplasias/fisiopatologia , Padrões de Prática Médica/normas , Feminino , Conhecimentos, Atitudes e Prática em Saúde , Humanos , Internet , Gravidez , Taxa de Gravidez , Especialização , Inquéritos e QuestionáriosRESUMO
Our objective was to evaluate and characterize the extent and patterns of worldwide usage of preimplantation genetic screening (PGS) among the assisted reproductive technique community. A prospective, web-based questionnaire with questions relating to practices of, and views on, PGS was directed to users and non-users of PGS. A total of 386 IVF units from 70 countries conducting 342,600 IVF cycles annually responded to the survey. A total of 77% of respondents routinely carry out PGS in their clinics for a variety of indications: advanced maternal age (27%), recurrent implantation failure (32%) and recurrent pregnancy loss (31%). Few (6%) offer PGS to all their patients. In most cycles (72%), trophectoderm biopsy is carried out and either array-comparative genomic hybridization (59%) or next-generation sequencing (16%) are used for genetic analysis. Only 30% of respondents regard PGS as clearly evidenced-based, and most (84%) believe that more randomized controlled trials are needed to support the use of PGS. Despite ongoing debate and lack of robust evidence, most respondents support the use of PGS, and believe that it may aid in transferring only euploid embryos, thereby reducing miscarriage rates and multiple pregnancies, increasing live birth rates and reducing the risk of aneuploid pregnancies and births.
Assuntos
Testes Genéticos/estatística & dados numéricos , Diagnóstico Pré-Implantação/estatística & dados numéricos , Humanos , Internacionalidade , Inquéritos e QuestionáriosRESUMO
We evaluated the clinical utility of screening for mutations in 34 breast/ovarian cancer susceptibility genes in high-risk families in Israel. Participants were recruited from 12, 2012 to 6, 2015 from 8 medical centers. All participants had high breast/ovarian cancer risk based on personal and family history. Genotyping was performed with the InVitae™ platform. The study was approved by the ethics committees of the participating centers; all participants gave a written informed consent before entering the study. Overall, 282 individuals participated in the study: 149 (53 %) of Ashkenazi descent, 80 (28 %) Jewish non-Ashkenazi descent, 22 (8 %) of mixed Ashkenazi/non-Ashkenazi origin, 21 (7 %) were non-Jewish Caucasians, and the remaining patients (n = 10-3.5 %) were of Christian Arabs/Druze/unknown ethnicity. For breast cancer patients (n = 165), the median (range) age at diagnosis was 46 (22-90) years and for ovarian cancer (n = 15) 54 (38-69) years. Overall, 30 cases (10.6 %) were found to carry a pathogenic actionable mutation in the tested genes: 10 BRCA1 (3 non-founder mutations), 9 BRCA2 (8 non-founder mutations), and one each in the RAD51C and CHEK2 genes. Furthermore, actionable mutations were detected in 9 more cases in 4 additional genes (MSH2, RET, MSH6, and APC). No pathogenic mutations were detected in the other genotyped genes. In this high-risk population, 10.6 % harbored an actionable pathogenic mutation, including non-founder mutations in BRCA1/2 and in additional cancer susceptibility genes, suggesting that high-risk families should be genotyped and be assigned a genotype-based cancer risk.
Assuntos
Família , Predisposição Genética para Doença , Testes Genéticos , Mutação em Linhagem Germinativa , Síndrome Hereditária de Câncer de Mama e Ovário/diagnóstico , Síndrome Hereditária de Câncer de Mama e Ovário/genética , Feminino , Síndrome Hereditária de Câncer de Mama e Ovário/epidemiologia , Humanos , Israel/epidemiologia , Masculino , Programas de RastreamentoAssuntos
Aneuploidia , Diagnóstico Pré-Natal/métodos , Adulto , Amniocentese/efeitos adversos , Amostra da Vilosidade Coriônica/efeitos adversos , Protocolos Clínicos , Consenso , DNA/sangue , Síndrome de Down/diagnóstico , Feminino , Sangue Fetal/química , Idade Gestacional , Humanos , Idade Materna , Guias de Prática Clínica como Assunto , Gravidez , Primeiro Trimestre da Gravidez , Segundo Trimestre da Gravidez , Fatores de Risco , Sociedades Médicas , Ultrassonografia Pré-NatalAssuntos
Síndrome do Cromossomo X Frágil/diagnóstico , Programas de Rastreamento , Diagnóstico Pré-Natal , Feminino , Proteína do X Frágil da Deficiência Intelectual/genética , Síndrome do Cromossomo X Frágil/genética , Síndrome do Cromossomo X Frágil/história , Triagem de Portadores Genéticos , História do Século XX , História do Século XXI , Humanos , Masculino , Mutação , Gravidez , Diagnóstico Pré-Natal/história , Diagnóstico Pré-Natal/métodosRESUMO
Methylenetetrahydrofolate reductase (MTHFR) deficiency is a rare autosomal recessive disorder. A novel homozygous MTHFR c.474A>T (p.G158G) mutation was detected in two unrelated children of Jewish Bukharian origin. This mutation generates an abnormal splicing and early termination codon. A carrier frequency of 1:39 (5/196) was determined among unrelated healthy Bukharian Jews. Given the disease severity and allele frequency, a population screening for individuals of this ancestry is warranted in order to allow prenatal, or preimplantation diagnosis.
Assuntos
Efeito Fundador , Homocistinúria/etnologia , Homocistinúria/genética , Judeus , Metilenotetra-Hidrofolato Redutase (NADPH2)/genética , Espasticidade Muscular/etnologia , Espasticidade Muscular/genética , Mutação , Alelos , Éxons , Feminino , Frequência do Gene , Heterozigoto , Humanos , Lactente , Masculino , Metilenotetra-Hidrofolato Redutase (NADPH2)/deficiência , Transtornos Psicóticos/etnologia , Transtornos Psicóticos/genética , Índice de Gravidade de Doença , Uzbequistão/epidemiologiaAssuntos
Síndrome de Down/diagnóstico , Complicações na Gravidez/diagnóstico , Diagnóstico Pré-Natal/métodos , Análise de Sequência de DNA/métodos , Adulto , Comitês Consultivos , Citogenética/métodos , Síndrome de Down/genética , Feminino , Aconselhamento Genético , Humanos , Agências Internacionais , Programas de Rastreamento/métodos , Gravidez , Complicações na Gravidez/genética , Diagnóstico Pré-Natal/normas , Sociedades Médicas , Translocação GenéticaRESUMO
INTRODUCTION: Most cases of cancer are sporadic and only 5%-10% are inherited with variable penetrance. Whenever the causative mutation is known, prevention of affected offspring birth may be achieved by prenatal or preimplantation genetic diagnosis (PGD). AIM: To devise a scoring system (SS) that appraises the justification of PGD for each patient and to evaluate the efficacy, reliability and accuracy of PGD for cancer predisposition syndromes in 48 cycles. METHODS: A semi-quantitative SS was developed by evaluating disease characteristics (onset, severity, inheritance pattern and penetrance) and patient clinical variables (infertility, objection to abortion and a need for diagnosis of additional genetic syndrome). PGD cycles were performed by blastomere biopsy of cleavage stage embryos, followed by single cell multiplex nested PCR for the cancer predisposition mutation and flanking polymorphic markers. RESULTS: Seventeen couples referred to PGD for cancer predisposition. According to the devised SS, fourteen were accepted and 3 were declined. Of the 14 accepted couples, 13 had at Least one affected member and 11 couples required IVF anyway. A total of 48 PGD cycles were performed resulting in 8 pregnancies. CONCLUSION: PGD for cancer predisposition genes is a possible and reliable procedure, suitable especiaLly for infertile carrier couples. DISCUSSION AND SUMMARY: The assessment of the characteristics of the cancer syndrome and consideration of the variables of each couple enable, the justified application of PGD procedure. The continuous discovery of cancer predisposition mutations will result in an ever-increasing demand for PGD to prevent the transmission of Lethal mutations to the next generations.
Assuntos
Predisposição Genética para Doença , Síndromes Neoplásicas Hereditárias/diagnóstico , Diagnóstico Pré-Implantação/métodos , Biópsia , Blastômeros/patologia , Feminino , Fertilização in vitro/métodos , Testes Genéticos/métodos , Humanos , Síndromes Neoplásicas Hereditárias/genética , Gravidez , Reprodutibilidade dos TestesAssuntos
Aneuploidia , Complicações na Gravidez/diagnóstico , Diagnóstico Pré-Natal/métodos , Sociedades Médicas , Comitês Consultivos , Técnicas de Laboratório Clínico , Consenso , Eficiência , Feminino , Humanos , Agências Internacionais/legislação & jurisprudência , Programas de Rastreamento/métodos , Obstetrícia/legislação & jurisprudência , Obstetrícia/métodos , Obstetrícia/organização & administração , Gravidez , Complicações na Gravidez/genética , Diagnóstico Pré-Natal/normas , Sociedades Médicas/legislação & jurisprudênciaRESUMO
PURPOSE: To determine the frequency of SMN1 deletion carriers in the Israeli population and to assess the feasibility of population screening for spinal muscular atrophy. METHODS: A total of 6394 individuals without family history of spinal muscular atrophy underwent genetic screening by multiplex ligation-dependent probe amplification, designed to detect SMN1 exon 7 and exon 8 copy number. RESULTS: One hundred fifty-nine individuals carried an SMN1 heterozygous exon 7 deletion, yielding a carrier frequency of 1:40. About 10.8% of individuals were found to carry two or more SMN1 exon 7 copies on the same chromosome (cis configuration). This implies that some deletion carriers may not be detected by multiplex ligation-dependent probe amplification or similar quantitative methods. The acceptance of spinal muscular atrophy screening among women undergoing testing for fragile X syndrome and cystic fibrosis reached 93%. CONCLUSIONS: Currently used molecular techniques cannot detect about 5% of spinal muscular atrophy carriers with a cis configuration or individuals with SMN1 sequence mutations and de novo deletions. Thus, it is estimated that the spinal muscular atrophy carrier detection rate is about 90%. Given the severity of spinal muscular atrophy, the relatively high carrier frequency, and the estimated detection rate, we conclude that population-based screening for spinal muscular atrophy is feasible and acceptable.
Assuntos
Testes Genéticos , Heterozigoto , Atrofia Muscular Espinal/diagnóstico , Proteína 1 de Sobrevivência do Neurônio Motor/genética , Variações do Número de Cópias de DNA , Éxons/genética , Frequência do Gene , Humanos , Israel/epidemiologia , Atrofia Muscular Espinal/epidemiologia , Atrofia Muscular Espinal/genética , Deleção de SequênciaRESUMO
Joubert syndrome (JBTS), related disorders (JSRDs) and Meckel syndrome (MKS) are ciliopathies. We now report that MKS2 and CORS2 (JBTS2) loci are allelic and caused by mutations in TMEM216, which encodes an uncharacterized tetraspan transmembrane protein. Individuals with CORS2 frequently had nephronophthisis and polydactyly, and two affected individuals conformed to the oro-facio-digital type VI phenotype, whereas skeletal dysplasia was common in fetuses affected by MKS. A single G218T mutation (R73L in the protein) was identified in all cases of Ashkenazi Jewish descent (n=10). TMEM216 localized to the base of primary cilia, and loss of TMEM216 in mutant fibroblasts or after knockdown caused defective ciliogenesis and centrosomal docking, with concomitant hyperactivation of RhoA and Dishevelled. TMEM216 formed a complex with Meckelin, which is encoded by a gene also mutated in JSRDs and MKS. Disruption of tmem216 expression in zebrafish caused gastrulation defects similar to those in other ciliary morphants. These data implicate a new family of proteins in the ciliopathies and further support allelism between ciliopathy disorders.
Assuntos
Anormalidades Múltiplas/genética , Cílios/patologia , Proteínas de Membrana/genética , Mutação , Anormalidades Múltiplas/patologia , Sequência de Aminoácidos , Animais , Sequência de Bases , Linhagem Celular , Consanguinidade , Embrião de Mamíferos/embriologia , Embrião de Mamíferos/metabolismo , Gastrulação/genética , Regulação da Expressão Gênica no Desenvolvimento , Predisposição Genética para Doença , Proteínas de Fluorescência Verde/genética , Proteínas de Fluorescência Verde/metabolismo , Humanos , Hibridização In Situ , Judeus/genética , Microscopia Confocal , Dados de Sequência Molecular , Linhagem , Polimorfismo de Nucleotídeo Único , Interferência de RNA , Síndrome , Peixe-Zebra/embriologia , Peixe-Zebra/genéticaRESUMO
PURPOSE: A retrospective population study was conducted to determine the carrier frequencies of recently identified mutations in Oriental Jewish cystic fibrosis patients. METHODS: Data were collected from 10 medical centers that screened the following mutations: two splice site mutations-3121-1G>A and 2751 + 1insT-and one nonsense mutation-the Y1092X in Iraqi Jews. One missense mutation, I1234V, was screened in Yemenite Jews. RESULTS: A total of 2499 Iraqi Jews were tested for one, two, or all three mutations. The 3121-1G>A, Y1092X, and 2751 + 1insT mutations had a carrier frequency of 1:68.5, 1:435, and 0, respectively. In 1435 Yemenite Jews screened, I1234V had a carrier frequency of 1:130. CONCLUSION: The 0.84% allele frequency of the three Iraqi founder mutations falls within the Israeli Society of Medical Geneticists' inclusion criteria for screening of 1:60 carrier frequency; hence, Iraqi Jews were added to the carrier screening policy with a panel including the three Iraqi founder mutations in addition to the five Ashkenazi mutations previously detected in Eastern Jews. 2751 + 1insT that was detected in patients only was included in the screening panel to increase the detection rate. I1234V does not meet the inclusion criteria but is now offered on a diagnostic basis and can be added to the screening panel for individuals whose mixed origin includes Yemenite, in addition to protocol-recommended origins. This study demonstrates the dynamic modifications of the Israeli carrier cystic fibrosis screening protocol based on newly detected founder mutations in a large cohort, taking into account mutation impact and intercommunal admixture.
Assuntos
Fibrose Cística/etnologia , Triagem de Portadores Genéticos/métodos , Testes Genéticos/métodos , Judeus/genética , Fibrose Cística/genética , Frequência do Gene , Humanos , Israel/etnologia , Mutação , Grupos Populacionais/genética , Estudos RetrospectivosRESUMO
Mutations in the gene Indian Hedgehog (IHH) that cause Brachydactyly A-1 (BDA1) have been restricted to a specific region of the N-terminal active fragment of Indian Hedgehog involving codons 95, 100, 131, and 154. We describe two novel mutations in codons 128 and 130, not previously implicated in BDA1. Furthermore, we identified an independent mutation at codon 131 and we also describe a New Zealand family, which carries the 'Farabee' founder mutation and haplotype. All of the BDA1 mutations occur in a restricted area of the N-terminal active fragment of the IHH and are in contrast to those mutations causing an autosomal recessive acrocapitofemoral dysplasia, whose mutations are located at the distal N- and C-terminal regions of IHH-N and are physically separated from the BDA1-causing mutations. The identification of multiple independent mutations in codons 95, 100, and now in 131, implicate a discrete function for this region of the protein. Finally, we present a clinical review of all reported and confirmed cases of BDA1, highlighting features of the disorder, which add to the spectrum of the IHH mutations.
Assuntos
Deformidades Congênitas da Mão/genética , Proteínas Hedgehog/genética , Mutação , Sequência de Aminoácidos , Sequência de Bases , Códon , Análise Mutacional de DNA , Saúde da Família , Feminino , Efeito Fundador , Deformidades Congênitas da Mão/patologia , Humanos , Masculino , Dados de Sequência Molecular , Nova Zelândia , Linhagem , Homologia de Sequência de AminoácidosRESUMO
OBJECTIVE: To investigate the incidence of embryos' self-correction during preimplantation development in terms of mosaicism and in correlation with its developmental stage. DESIGN: Prospective study to compare the chromosome status of embryos on day 3 with that of day 5, in correlation with their developmental stage. SETTING: In vitro fertilization unit of a university-affiliated hospital. PATIENT(S): Eighty-three aneuploid embryos. INTERVENTION(S): Fluorescence in situ hybridization (FISH) reanalysis. MAIN OUTCOME MEASURE(S): Day 3 embryos classified as mosaic or chromosomally abnormal by preimplantation genetic screening (PGS) were reanalyzed on day 5. The results were evaluated in correlation with the embryos' developmental stage. RESULT(S): Out of 83 day 3 aneuploid embryos, 15 (18.1%) were diagnosed with mosaicism. The FISH reanalysis on day 5 demonstrated that 27 embryos (32.6%) were partly or entirely normal disomic. Of these 83 aneuploid embryos, 8 (9.7%) underwent complete self-correction. The PGS results demonstrated that 26.5% of the embryos were trisomic, of which 41.0% underwent trisomic rescue by day 5. Self-correction was in correlation with the embryo's developmental stage, i.e., 38.1% of aneuploid embryos that developed to the blastocyst stage underwent self-correction compared with only 12.5% of embryos that only cleaved after biopsy. CONCLUSION(S): Our results demonstrate that self-correction of aneuploid and mosaic embryos occurs probably more significantly during development toward the blastocyst stage than in delayed embryos. In addition, trisomic embryos correct themselves more than other aneuploidies. These findings suggest that PGS results must be interpreted with caution.
Assuntos
Aneuploidia , Blastocisto/fisiologia , Desenvolvimento Embrionário/fisiologia , Diagnóstico Pré-Implantação , Adulto , Biópsia , Blastocisto/patologia , Análise Citogenética/métodos , Feminino , Fertilização in vitro/métodos , Testes Genéticos/métodos , Humanos , Hibridização in Situ Fluorescente , Gravidez , Prognóstico , Estudos ProspectivosRESUMO
OBJECTIVE: Isolated nonvisualized fetal gallbladder (INVFGB) is relatively rare. In most cases, the gallbladder will eventually be detected. In some cases however, INVFGB may be associated with serious abnormalities, cystic fibrosis (CF), aneuploidy, and agenesis of the gall bladder. We describe a clinical evaluation of prenatally diagnosed INVFGB. METHODS: Cases of nonvisualized gallbladder were first evaluated by serial scans. Cases with no additional malformations were designated as INVFGB, and were further evaluated by mutation analysis for CF, and amniocentesis for karyotype and microvillar membrane enzymes (MME). RESULTS: A total of 22 cases of nonvisualized gallbladder were detected. Of these, 2 had additional malformations, and 3 were excluded because of incomplete evaluation. Of the remaining 17 cases, 3 (17.6%) had adverse outcomes: 1 case of CF, 1 case of 47,XXX, and 1 case of multiple congenital anomalies detected only postnatally. Abnormal levels of MMEs were detected in 3 cases, 1 of which was diagnosed with CF. In 2 cases, the gallbladder was not detected even after birth, but development is normal. CONCLUSION: Evaluation of INVFGB should include genetic counselling, amniocentesis for karyotype and MME analysis, CFTR mutation analysis and repeated ultrasound scans.